Drugs / Incobotulinumtoxin type A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07624045 | Jul 2026 → Jan 2029 expected | piriformis syndrome | Nîmes University Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Incobotulinumtoxin type A | “Incobotulinumtoxin type A (200 U in 2 mL of preservative-free normal saline) will be injected in equally divided doses” NCT07624045 ↗ |
| Route | Intramuscular | “administration into the piriformis muscle” NCT07624045 ↗ |